The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS, N.J. , Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology® Cl...
Quest Diagnostics Incorporated announced its Q3 earnings yesterday - revenues year-to-date are $8.23bn, and net income $845m. DGX is finally demonstrating a strong post-pandemic recovery, with Q3 revenues up 13% and ambitious growth initiatives in advanced diagnostics and strategic partnerships. DGX's diverse client base, operational improvements, and recent acquisitions position it for steady,...
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Shawn Bevec - Vice President of Investor Relations James Davis - Chairman, CEO & President Sam Samad - Executive VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Elizabeth Anderson - ...
Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.
Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to...
Quest Diagnostics (DGX) remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas. It has proven itself as a cashflow and dividend grower, achieving strong margins among peers and similar competitor Labcorp, and making progress on FDA approvals.
Quest Diagnostics Incorporated (NYSE:DGX ) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDT Company Participants Sam Samad - Executive VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay, we're going to kick it off. I'm Tycho Peterson from the life science team at Je...
SECAUCUS, N.J. , Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.